Heffernan Michael Thomas

October 12, 2026

TRVI releases Q2 2026 earnings and makes Raymond James top health list. Trevi Therapeutics held its Q2 2026 earnings call, sharing the latest financial and operational results. In a separate note, Raymond James analysts listed the stock among their top four healthcare picks. The earnings discussion and analyst endorsement may draw additional attention to the company. The shares are trading close to the upper end of their 52‑week range.

October 15, 2026

COLL Outlook Supported by ADHD Trends, Low Generic Risk, Oppenheimer. Oppenheimer notes that Collegium Pharmaceutical's outlook is bolstered by strong demand for ADHD treatments and a low risk of generic competition. The firm’s focus on these areas may help sustain revenue growth. The stock is currently trading near its 52‑week low of $21.43, close to a support level that has been tested repeatedly.

October 13, 2026

Biohaven signs $100M deal with Ono for IgG degraders. Biohaven has entered a strategic licensing agreement with Ono Pharma for its IgG degrader technology in Japan and select Asian regions. The deal includes up to $100 million in near-term payments, with $80 million paid upfront. This move expands the company's presence in Asia and supports its lead candidate, BHV-1300, which is currently in Phase 3 trials for Graves' disease.